Pharmaceutical Go-To-Marketand LaunchStrategy
Most launch plans fail in the gap between global brand strategy and what a local market will pay for, prescribe and reimburse. Egypt has its own pricing rules, tender structures, insurance transition and physician economics. We plan against those, not around them.
In short
Hibridge builds and executes go-to-market plans for pharmaceutical products entering Egypt and MENA markets. Work covers market and competitor assessment, pricing and access positioning, segmentation and targeting, channel mix, field-force enablement, launch-readiness milestones, and the first-year tracking that shows whether the plan is holding.
What we do
Launch sequencing built around what the market will reimburse.
Market and opportunity assessment
Epidemiology, treatment pathway mapping, competitor share and the addressable patient population, sized rather than asserted.
Pricing and access positioning
Reference pricing exposure, how tenders and public procurement work, and positioning against the Universal Health Insurance rollout as it reaches each governorate.
Segmentation and targeting
Prescriber segmentation by potential and behaviour, account prioritisation, and a call plan the field force can run.
Launch readiness
Milestone plan from pre-launch to first-year review, with clear gates and a named owner on each.
Field-force enablement
Detail aids, objection handling, training and rehearsal. All checked by our compliance team before the first cycle meeting.
Launch performance tracking
A metric set agreed before launch and reported against forecast, so correction happens in month three, not month eleven.
Approach
How we build a launch
- 01
Diagnose
Where the product wins, and against whom. Evidence over assumption.
- 02
Position
Access, pricing and clinical narrative resolved as one decision, not three.
- 03
Sequence
What happens in which month, who owns it, and what has to be true for the next step to start.
- 04
Execute and correct
Delivery against the plan with a monthly read on the agreed metrics.
Why it matters
Launch underperformance is not an edge case. It is the norm. Half of the 2023 US launch class came in below its own pre-launch forecast, and first-time launchers do worse than established players.
50%
Half of the 2023 US pharmaceutical launch class underperformed its pre-launch first-year revenue forecast.
Trinity Life Sciences, 2024
20 to 30%
Over the past five years, only 20 to 30 percent of first-time launchers exceeded launch expectations, against 40 to 50 percent for established companies.
McKinsey & Company, 2024
EGP 422bn
The market, 2025
Egypt's pharmaceutical market reached EGP 422 billion in 2025, roughly US$8.5 billion across 4 billion units. It grew 37% year on year and moved from 30th to 26th place globally.
≈ Egyptian Drug Authority, 2026
Every figure names its publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
Do you work on pre-launch, or only at launch?
Pre-launch is where the costliest decisions are made: pricing exposure, evidence gaps, KOL sequencing. Engaging twelve to eighteen months out is normal.
Can you work alongside our global brand team?
Yes, and usually the point is translation: taking a global strategy and resolving it against Egyptian pricing, tender and reimbursement reality without breaking brand consistency.
Do you cover generics and biosimilars?
Yes. The commercial logic differs from innovator launches. Tender positioning and cost-of-goods discipline matter more than share of voice, and we plan for that.
Related services